SLC13A5 and metabolic dysfunction-associated steatotic liver disease: Targeted inhibition of SLC13A5/Mindy in the liver recapitulated many of the effects of the SLC13A5/Mindy knockout mouse on diet-induced nonalcoholic fatty liver disease (Brachs et al., 2016).